Clinical Trials Logo

Infectious Mononucleosis clinical trials

View clinical trials related to Infectious Mononucleosis.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04138875 Withdrawn - Clinical trials for Hematopoietic/Lymphoid Cancer

A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

Start date: January 2022
Phase: Phase 2
Study type: Interventional

This is an open label, risk-stratified, sequential treatment, phase 2 study of newly diagnosed post-transplant lymphoproliferative disorders with positive CD20 and CD30 expression. It includes an induction phase with rituximab and brentuximab vedotin (RBv), followed by a treatment phase with RBv or RBv in combination with bendamustine (RBvB) based on response to induction. The primary end point is treatment efficacy measured as the overall response rate (ORR) and progression free survival (PFS).